Source disclosure: March 02, 2026, 11:30 JST
Published by Pulse News Wire: March 02, 2026, 11:37 JST
Nano Holdings,Inc. [4571.T]
TOKYO, Mar 02 (Pulse News Wire) – Nano Holdings,inc. (4571.T) completed the first patient dosing in its Phase 1 clinical trial for RUNX1 mRNA treatment of knee osteoarthritis in Australia.
The trial, conducted by the company's subsidiary PrimRNA, marks the world’s first mRNA drug administration directly into the knee joint in humans. This milestone was achieved through collaborative efforts involving medical teams from Royal Adelaide Hospital, local contract research organizations (CROs), and Nano Holdings' development team.
The international collaboration ensured smooth operational procedures and readiness for subsequent phases of the trial. "We are committed to ensuring patient safety while advancing this groundbreaking study," said CEO Jun Matsumura.
"Our combined Japanese-Australian team will continue to push forward with full force." The company noted that there would be no impact on its fiscal year 2026 performance due to this achievement but pledged to disclose any significant developments promptly.
AI-translated content. 🟢 Confidence: High See terms • Original filing